| Drug General Information |
| Drug ID |
D0K9JP
|
| Former ID |
DNC004664
|
| Drug Name |
A-80426
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Terminated |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H27NO2
|
| Canonical SMILES |
CN(CCC1=CC2=C(C=C1)C=CO2)CC3CCCC4=C3C=CC=C4OC
|
| InChI |
1S/C23H27NO2/c1-24(13-11-17-9-10-18-12-14-26-23(18)15-17)16-19-5-3-7-21-20(19)6-4-8-22(21)25-2/h4,6,8-10,12,14-15,19H,3,5,7,11,13,16H2,1-2H3/t19-/m0/s1
|
| InChIKey |
MHPMXTGKTXJIDI-IBGZPJMESA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[2]
|
|---|
| 5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[3]
|
| 5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[3]
|
| D(2) dopamine receptor |
Target Info |
Inhibitor |
[3]
|
| Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[2]
|
| Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[4]
|
| D(4) dopamine receptor |
Target Info |
Inhibitor |
[2]
|
| Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04024:cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Serotonergic synapsehsa04020:Calcium signaling pathway
|
|
Gap junction
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channelshsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04726:Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04022:cGMP-PKG signaling pathway
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP04373:5HT1 type receptor mediated signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
5HT3 type receptor mediated signaling pathway
|
|
5HT4 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390666:Serotonin receptors
|
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390696:Adrenoceptors
|
|
G alpha (z) signalling eventsR-HSA-390651:Dopamine receptors
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
|
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Nicotine Activity on Dopaminergic NeuronsWP58:Monoamine GPCRs
|
|
GPCR downstream signalingWP727:Monoamine Transport
|
|
NRF2 pathway
|
|
Synaptic Vesicle Pathway
|
|
Serotonin Transporter ActivityWP666:Hypothetical Network for Drug Addiction
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006017) |
|---|
| REF 2 | J Med Chem. 2005 Mar 24;48(6):2054-71.Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity. |
|---|
| REF 3 | J Med Chem. 2005 Oct 20;48(21):6523-43.Designed multiple ligands. An emerging drug discovery paradigm. |
|---|
| REF 4 | J Med Chem. 1997 Mar 28;40(7):1049-62.Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT uptake inhibitingand alpha2-antagonistic activities. |
|---|
